EGFR20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识(2024版)

Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

表皮生长因子受体(epidermal growth factor receptor,EGFR)20外显子插入(exon 20 insertion,ex20ins)突变非小细胞肺癌(non-small cell lung cancer,NSCLC)的规范化诊疗在《EGFR 20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识(2023版)》中进行了阐述,提高了临床医生对该罕见靶点的关注。随着疾病领域探索的深入及新型靶向药物的获批,EGFR ex20ins NSCLC的诊疗策略也随之更新。本共识在2023版中国专家共识的基础上进行更新,专家组通过参考国内外文献及临床数据并结合专家自身临床经验,分别从疾病认知、疾病检测、疾病治疗和新型靶向药物研发现状等方面更新共识性建议,以期更好地为临床医师提供用药参考。

The standard clinical practice of managing the non-small cell lung cancer(NSCLC)with epider-mal growth factor receptor(EGFR)exon 20 insertion(ex20ins)mutations was elaborated in Chinese expert consensus on non-small cell lung cancer with EGFR exon 20 insertion mutations(2023 edition),and this rare subset has gradually attracted attention recently.With the deepening of treatment area exploration and the approval of new targeted drugs,there are more options for the diagnosis and treatment of EGFR ex20ins positive NSCLC patients.Therefore,based on the previous version of consensus,the expert panel has updated this consensus on the standardized clinical diagnosis and treatment of EGFR ex20ins mutation NSCLC through reference to literature and clinical data,and combined with the experts'own clinical experience.The updated recommendations includes disease congnition,testing methods,therapy and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation,in order to provide better medication reference for clinical physicians.